Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in:

Open Access 01-12-2017 | Commentary

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer

Authors: Xiaoming Liu, William C. Cho

Published in: Clinical and Translational Medicine | Issue 1/2017

Login to get access

Abstract

Immune checkpoint blockade therapy by targeting the programmed death protein 1/programmed death ligand 1 (PD-L1) axis using antibodies has yielded promising clinical responses in patients with non-small cell lung cancer (NSCLC). However, owing to the dynamic expression of PD-L1, degree of mutational/neoantigen load, intratumoral heterogeneity, infiltrated immune cells of tumor microenvironment of NSCLC, the response rates to these agents are limited, despite several companion diagnostic assays by detecting PD-L1 in tumor cells have been introduced into clinical practice. Therefore, in this era of precision medicine, there is an urgent need for predictive biomarkers to identify NSCLC patients likely to benefit from this novel therapy.
Literature
1.
Ma W, Gilligan BM, Yuan J, Li T (2016) Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 9(1):47CrossRefPubMedPubMedCentral
2.
Yang J, Chen J, Wei J, Liu X, Cho WC (2016) Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Expert Opin Biol Ther 16(10):1209–1223CrossRefPubMed
3.
Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R (2016) FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21(5):643–650CrossRefPubMedPubMedCentral
4.
Genentech (2016) First anti-PD-L1 drug approved for NSCLC. Cancer Discov 6(12):OF1
5.
Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13(3):143–158CrossRefPubMed
6.
Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K et al (2016) PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the “Blueprint PD-L1 IHC Assay Comparison Project”. J Thorac Oncol. doi:10.​1016/​j.​jtho.​2016.​11.​2228
7.
Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ et al (2016) P2.39: long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab: track: immunotherapy. J Thorac Oncol 11(10S):S241–S242CrossRefPubMed
8.
Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M et al (2016) A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol 11(11):1846–1855CrossRefPubMed
9.
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497–1508CrossRefPubMed
10.
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837–1846CrossRefPubMed
11.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128CrossRefPubMedPubMedCentral
12.
Giri A, Walia SS, Gajra A (2016) Clinical trials investigating immune checkpoint inhibitors in non-small-cell lung cancer. Rev Recent Clin Trials 11(4):297–305CrossRefPubMed
13.
14.
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463–1469CrossRefPubMedPubMedCentral
15.
Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY (2016) Imaging biomarkers in immunotherapy. Biomark. Cancer 8(suppl 2):1–13
16.
Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G (2016) High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics 6(10):1629–1640CrossRefPubMedPubMedCentral
17.
Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O et al (2016) Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab. Sci Rep 6:31726CrossRefPubMedPubMedCentral
Metadata
Title
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
Authors
Xiaoming Liu
William C. Cho
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2017
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-017-0136-7

Other articles of this Issue 1/2017

A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet

  • Open Access
  • Review

Expression of Concern to: Role of physiotherapy in the mobilization of patients with spinal cord injury undergoing human embryonic stem cells transplantation

  • Open Access
  • Erratum

Lessons from the swamp: developing small molecules that confer salamander muscle cellularization in mammals

  • Open Access
  • Commentary

Autophagy and inflammation

  • Open Access
  • Review

Proteomics in asthma: the clinicians were right after all, were not they?

  • Open Access
  • Commentary

The role of heterogeneity in asthma: a structure-to-function perspective

  • Open Access
  • Review